These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27835061)

  • 1. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
    Boccia A; Virata C; Lindner D; English N; Pathan N; Brickelmaier M; Hu X; Gardner JL; Peng L; Wang X; Zhang X; Yang L; Perron K; Yco G; Kelly R; Gamez J; Scripps T; Bennett D; Joseph IB; Baker DP
    J Interferon Cytokine Res; 2017 Jan; 37(1):20-31. PubMed ID: 27835061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
    Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
    Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.
    Michaelson JS; Kelly R; Yang L; Zhang X; Wortham K; Joseph IB
    Cancer Biol Ther; 2012 Jul; 13(9):812-21. PubMed ID: 22669574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms.
    Asano M; Matsui J; Towle MJ; Wu J; McGonigle S; DE Boisferon MH; Uenaka T; Nomoto K; Littlefield BA
    Anticancer Res; 2018 Jun; 38(6):3375-3385. PubMed ID: 29848686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
    Hu X; Seddighzadeh A; Stecher S; Zhu Y; Goyal J; Matson M; Marbury T; Smith W; Nestorov I; Hung S
    J Clin Pharmacol; 2015 Feb; 55(2):179-88. PubMed ID: 25187030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Hoy SM
    CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
    Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
    J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
    Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
    Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin.
    Bauer JA; Morrison BH; Grane RW; Jacobs BS; Dabney S; Gamero AM; Carnevale KA; Smith DJ; Drazba J; Seetharam B; Lindner DJ
    J Natl Cancer Inst; 2002 Jul; 94(13):1010-9. PubMed ID: 12096086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics.
    Kundu S; Fan K; Cao M; Lindner DJ; Tuthill R; Liu L; Gerson S; Borden E; Yi T
    Mol Cancer Ther; 2010 Aug; 9(8):2287-96. PubMed ID: 20682647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
    Roh MR; Zheng Z; Kim HS; Jeung HC; Rha SY; Chung KY
    Melanoma Res; 2013 Apr; 23(2):114-24. PubMed ID: 23358428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.